Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells

European Neurology

Volumn 63, Issue 5, 2010, Pages 311-317

  Putzki, Norman ^a,c   Baranwal, Manoj Kumar ^d   Tettenborn, Barbara ^c   Limmroth, Volker ^a,b   Kreuzfelder, Ernst ^d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d THAPAR UNIVERSITY   (India)

Author keywords

Crohn's disease; Multiple sclerosis; Natalizumab; Natural killer cells; Regulatory T cells

Indexed keywords

BETA INTERFERON; GLATIRAMER; NATALIZUMAB; VERY LATE ACTIVATION ANTIGEN 4;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LONGITUDINAL STUDY; LYMPHOCYTE FUNCTION; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

EID: 77951954050     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000302687     Document Type: Article

References (42)

1. Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, et al: Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997; 8: 3-16.
2. Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, et al: Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 2007; 64: 169-176.
3. Burkly LC, Jakubowski A, Newman BM, Rosa MD, Chi-Rosso G, Lobb RR: Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation. Eur J Immunol 1991; 21: 2871-2875.
4. Damle NK, Aruffo A: Vascular cell adhesion molecule 1 induces T-cell antigen receptordependent activation of CD4+ T lymphocytes. Proc Natl Acad Sci USA 1991; 88: 6403-6407.
5. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N: Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66.
6. Lobb RR, Hemler ME: The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 1994; 94: 1722-1728.
7. Sandborn WJ, Yednock TA: Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 2003; 98: 2372-2382.
8. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
9. von Andrian UH, Engelhardt B: Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348: 68-72.
10. Niino M, Bodner C, Simard ML, Alatab S, Gano D, et al: Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59: 748-754.
11. Stuve O, Marra CM, Bar-Or A, Niino M, Cravens PD, et al: Altered CD4+/CD8+ Tcell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006; 63: 1383-1387.
12. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, et al: Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59: 743-747.
13. Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E: Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71: 1350-1354.
14. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 1006; 354: 911-923.
15. Baecher-Allan C, Hafler DA: Suppressor T cells in human diseases. J Exp Med 2004; 10: 273-276.
16. Sakaguchi S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and nonself. Nat Immunol 2005; 6: 345-352.
17. Feger U, Luther C, Poeschel S, Melms A, Tolosa E, et al: Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 2007; 147: 412-418.
18. Haas J, Hug A, Viehover A, Fritzsching B, Falk CS, et al: Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005; 35: 3343-3352.
19. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA: Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971-979.
20. McFarland HF, Martin R: Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007; 8: 913-919.
21. Kumar M, Putzki N, Limmroth V, Remus R, Lindemann M, Knop D, Mueller N, Hardt C, Kreuzfelder E, Grosse-Wilde H: CD4+ CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J Neuroimmunol 2006; 180: 178-184.
22. Theien BE, Vanderlugt CL, Eagar TN, Nickerson-Nutter C, Nazareno R, et al: Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 2001; 107: 995-1006.
23. Ditschkowski M, Kreuzfelder E, Rebmann V, Ferencik S, Majetschak M, Schmid EN, Obertacke U, Hirche H, Schade UF, Grosse-Wilde H: HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 1999; 229: 246-254.
24. Hauser SL, Waubant E, Arnold DL, et al: BCell depletion with rituximab in relapsingremitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
25. Niino M, Bodner C, Simard ML, Alatab S, Gano D, et al: Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59: 748-754.
26. Ransohoff RM: Natalizumab and PML. Nat Neurosci 2005; 8: 1275.
27. Stenner MP, Waschbisch A, Buck D, Doerck S, Einsele H, et al: Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS One 2008; 3:e3319.
28. Putzki N, Kumar M, et al: Mitoxantrone does not restore the impaired suppressive function of natural T regulatory cells in patients suffering from multiple sclerosis: a longitudinal ex vivo and in vitro study. Eur Neurol 2009; 61: 27-32.
29. Hong J, Li N, Zhang X, Zheng B, Zhang JZ: Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005; 102: 6449-6454.
30. de Andres C, Aristimuno C, de Las Heras V, Martinez-Gines ML, Bartolome M, et al: Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007; 182: 204-211.
31. Kleinschnitz C, Meuth SG, Kieseier BC, Wiendl H: Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies. Endocr Metab Immune Disord Drug Targets 2007; 7: 35-63.
32. Bluestone JA, Thomson AW, Shevach EM, Weiner HL: What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol 2007; 7: 650-654.
33. Kastrukoff LF, Lau A, Wee R, Zecchini D, White R, Paty DW: Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J Neuroimmunol 2003; 145: 103-114.
34. Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW: A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol 1998; 86: 123-133.
35. Oger J, Kastrukoff LF, Li DK, Paty DW: Multiple sclerosis: in relapsing patients, immune functions vary with disease activity as assessed by MRI. Neurology 1988; 38: 1739-1744.
36. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R: Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2-Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 5941-5946.
37. Saraste M, Irjala H, Airas L: Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007; 28: 121-126.
38. Guiliani M, Giron-Michel J, Negrini S: Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15. PLoS One 2008; 3:e2241.
39. Houff SA, Major EO, Katz D, et al: Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988; 318: 301-305.
40. Sabath B, Major E: Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186:S180-S186.
41. Wei G, Liu CK, Atwood WJ: JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J Neurovirol 2000; 6: 127-136.
42. Belkaid Y: Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007; 7: 875-888